AMENDMENT

Please amend the claims to read as follows:

1-49 (canceled).

50. (currently amended) A method of ameliorating pain and inflammation in a subject, comprising transdermally administering to said subject, an amount of an aconitine alkaloid selected from the group consisting of: lappaconitine, 3-acetylaconitine, and bulleyaconitine A which is sufficient to achieve an aconitine alkaloid blood plasma level of from about 0.5 to about 400 ng/ml.

51. (original) A method as set forth in claim 50, wherein the transdermal administration the aconitine alkaloid is sufficient to achieve an aconitine alkaloid blood plasma level of from about 0.5 to about 200 ng/ml.

52. (original) A method as set forth in claim 50, wherein the aconitine alkaloid blood plasma level is achieved within about 0.25 to about 18 hours after initiation of the aconitine alkaloid administration.

53. (original) A method as set forth in claim 50, wherein the aconitine alkaloid blood plasma level is achieved within about 0.5 to about 12 hours after initiation of the aconitine alkaloid administration.

54. (original) A method as set forth in claim 50, wherein the aconitine alkaloid blood plasma level is sustained for a duration of at least about 24-96 hours from a single transdermal administration.